Global leader in 3D printing pharmaceuticals
Pioneer of new digital pharmaceutical processes
Founded in July 2015, Triastek is dedicated to the mission of "revolutionizing the pharmaceutical industry, unlocking the next generation of medicine and benefitting patients worldwide." We have created the Melt Extrusion Deposition (MED®) 3D printing pharmaceutical process, transforming the delivery, development, and production of medicines through digital product development and continuous manufacturing.
Leveraging our proprietary 3D printing pharmaceutical technology, we design and develop transformative medicines for patients. Through collaboration with global pharmaceutical companies, we tackle challenging formulation problems, accelerating the development of new drug products and improving the quality of pharmaceuticals.
Our vision is to become the world's most influential intelligent pharmaceutical enterprise.
262
Patent Applications
99
Granted Patents
12
Territories
Founder and CEO
Co-founder and CSO
Triastek originated from a scientific hypothesis by Professor Xiaoling Li:
Applying 3D printing technology for revolutionizing the development and production of pharmaceutical products.CE
CP Advisor
Experienced Recruitment
Campus Recruitment
BD@triastek.com
苏ICP备17053162号 苏公网安备 32011502011777号
All Rights Reserved
Copyright © 2025 (TRIASTEK)
Contact Us
BD@triastek.comCOPYRIGHT © 2025 TRIASTEK. 苏ICP备17053162号
DIGITAL By VTHINK